Medical Devices

Taiwanese biotech GlycoNex will begin human trials for GNX1021, a novel ADC that targets cancer's unique sugar coating to fight GI tumors.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.

A new report reveals a major gap in AI adoption as digital disruptors and generic GLP-1s force Canadian pharmacies to innovate or risk being left behind.

European non-profit ELRIG launches its first US conference, a free-to-attend event aiming to connect scientists and tackle intractable drug targets.

FDA clearance for a new neurovascular catheter promises greater precision and expands less invasive options for stroke and brain bleed procedures.

A landmark grant funds research into scaffold-free tissue, a revolutionary approach that could one day eliminate the need for many knee replacements.

A global partnership aims to bring Atla-cel, a next-gen CAR-T therapy with low neurotoxicity, to children with leukaemia, potentially revolutionizing treatment.

Amid rising industry risks, EmPRO reports a stellar 77.4% combined ratio and 47% surplus growth, signaling stability and strategic expansion for doctors.

The medical device firm reports 20% Q1 revenue growth, fueled by new billing codes that boost Barostim approvals and a trial to triple its patient base.

With new funding, ImageneBio advances its unique OX40 inhibitor, IMG-007, for eczema and alopecia, but faces a divided Wall Street.

The FDA has cleared the first 'theragnostic' sleep apnea device, integrating treatment and monitoring to usher in an era of data-driven, personalized care.

With over 4.5 million dog bites annually, experts urge families to look beyond breed and focus on education to protect both children and pets.

With a new CEO from rival InMode and backing from a global powerhouse, Boston Aesthetics is poised to shake up the competitive medical aesthetics industry.

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

Biotech firm Epitopea adds top expert Dr. Lisa Butterfield, validating its novel RNA vaccine approach targeting hidden cancer antigens for hard-to-treat tumors.

A family's personal journey with a rare disorder sparks a major investment in Quiver Bioscience's AI-powered therapy, aiming to treat Dup15q syndrome.

With NHS lists at 7.4M and implants costing a year's salary, half a million Brits now fly to Türkiye for dental care. Is it a perfect solution or a risky bet?

With the key hire of a new commercial VP, Grey Wolf Animal Health aims to unlock synergies between its booming pharmacy and animal health divisions.

VITAL MedTech unveils a bold vertical integration strategy, leveraging its parent's semiconductor mastery to build imaging systems from raw materials to final scans.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.